The ABD-Irisin fusion protein extends its plasma half-life to approximately 10 hours and enhances its anti-inflammatory efficacy by suppressing the TLR4-MyD88-NF-κB pathway, offering a potent therapeutic candidate for inflammatory diseases.
- Jicun Zhu
- Yujie Zhang
- Jianxiang Shi
